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Abstract
Optical imaging of breast cancer has been considered for detecting functional and molecular characteristics of dis-
eases in clinical and preclinical settings. Applied to laboratory research, photonic investigations offer a highly ver-
satile tool for preclinical imaging and drug discovery. A particular advantage of the optical method is the availability
of multiple spectral bands for performing imaging. Herein, we capitalize on this feature to demonstrate how it is pos-
sible to use different wavelengths to offer internal controls and significantly improve the observation accuracy in
molecular imaging applications. In particular, we show the independent in vivo detection of cysteine proteases along
with tumor permeability and interstitial volume measurements using a dual-wavelength approach. To generate re-
sults with a view toward clinically geared studies, a transgenic Her2/neumouse model that spontaneously developed
mammary tumors was used. In vivo findings were validated against conventional ex vivo tests such as histology and
Western blot analyses. By correcting for biodistribution parameters, the dual-wavelength method increases the accu-
racy of molecular observations by separating true molecular target from probe biodistribution. As such, the method
is highly appropriate for molecular imaging studies where often probe delivery and target presence are not indepen-
dently assessed. On the basis of these findings, we propose the dual-wavelength/normalization approach as an es-
sential method for drug discovery and preclinical imaging studies.
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Introduction
With an increasing shift toward studying functional interactions at
the cellular and subcellular levels, postgenome biology can signifi-
cantly benefit from observation tools with the ability to offer quan-
titative functional and molecular parameters at different system
levels. Noninvasive fluorescence imaging has recently emerged as a
visualization tool with a high versatility in studying disease and thera-
peutic efficacy biomarkers. Largely enabled by the emergence of sev-
eral new adept fluorescence proteins and probes with high in vivo
labeling capacity, fluorescence observation has the potential to be-
come a mainstream biomedical investigation tool. A particular
strength lies with the use of advanced imaging methods, which, in
contrast to simple planar (photographic) imaging, can offer true
quantification and accuracy. Advanced imaging methods have now
been applied toward imaging cellular receptors [1–3], proteases [4–7],
and chemotherapeutic effects [8–10].
However, compared with other imaging modalities, fluorescence
molecular imaging is still confronted by the inability to independently
assess the amount of target present over the delivery of the molecular
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probe used. The particular difficulty is that most of fluorescence mo-
lecular imaging is currently static; that is, it is obtained after the probe
is delivered and after binding or activation processes have reached
steady state. As such, it contains no transients or dynamic features that
could be used to obtain delivery and uptake metrics. This is particu-
larly challenging when using molecular probes designed to stay in cir-
culation for long times [11] to maximize tumoral delivery. Thus, any
signal collected is a function of the target concentration and of the
probe’s availability at the target site (efficiency of probe delivery),
which can lead to significant quantification inaccuracies if not ac-
counted for. Furthermore, given that different tumor types and treat-
ment regimes (e.g., antiangiogenic treatment) can modulate cancerous
tissue permeability, accounting for target presence and biodistribution
at the region of interest (ROI) is of great importance.
As such, we consider a dual-wavelength strategy and show how it
can be used to improve on the coupled nature of fluorescence imag-
ing signals. Dual-wavelength imaging has been used before to resolve
multiple targets. For example, in a study done by Montet et al. [12],
two nearly identical vascular probes excitable at separate wavelengths
were used to monitor and measure vasculature volumes in mice and
observe different angiogenic inhibitor efficacies. Additionally, a study
done by Nahrendorf et al. [13] established how dual-channel imag-
ing could be used to investigate the spatiotemporal resolution of both
phagocytic and proteolytic activities mediated by macrophages and
neutrophils in the same mouse.
Instead, herein, we use one wavelength to image an activatable
fluorescent probe and a second wavelength to image a fluorescent
probe that reveals nonspecific probe delivery and uptake. By decom-
posing biodistribution specifics from the signals collected, accurate
target presence can then be inferred. We selected to visualize tumor
cathepsins and matrix metalloproteinases (MMPs) contents owing
to their elevated levels in cancers [14], using fluorescent probes that
do not emit fluorescence until they interact with proteases [15]. To
showcase the method in a clinically relevant tumor model, we used
a transgenic Her2/neu mouse model that spontaneously developed
focal mammary tumors. Doing so, we demonstrate improved accuracy
of the dual-wavelength approach over conventional single-wavelength
planar fluorescence imaging and discuss how the dual-wavelength
method yields a generic and essential strategy by which physiologi-
cal and molecular readings can be decomposed to offer true quantita-
tive readings.
Materials and Methods
Imaging System
Imaging was performed in normalized epi-illumination (reflec-
tance) imaging mode. Normalized epi-illumination is a technique
developed to overcome limitations of conventional photographic
approaches and corrects fluorescence signals by corresponding mea-
surements of light attenuation in tissue [16]. The imaging system
shown in Figure 1 allowed for epi-illumination data acquisition
and has been fully described before [17]. In short, white light illumi-
nation was achieved using a fluorescent bulb placed 30 cm from the
animal, whereas narrow band illumination was performed using two
672- and 748-nm CW laser diodes (B&W Tek, Newark, DE) routed
to an optical switch (DiCon FiberOptics, Berkley, CA) for multi-
modal and multispectral imaging. The laser output from the switch
was then directed to a beam expander that broadened the beam on
the surface of the animal. Photons generated within the animal were
then detected by a 512 × 512-pixel array CCD camera (Roper Sci-
entific, Trenton, NJ), outfitted with the appropriate band-pass filters
for the wavelengths used. Specifically, two different band-pass filters
(Andover, Salem, NH) were tuned at the excitation and emission
peaks of the fluorescent probes (AngioSense 670-Cy5.5 channel, ex-
citation: 670 ± 5 nm, emission: 710 ± 10 nm; and ProSense 750-
AF750 channel, excitation: 750 ± 5 nm, emission: 800 ± 20 nm). No
filter was used for white light images.
Animal Model and Imaging
In this study, FVB/N-Tg (MMTVneu) 202 Mul/J, (homozygous
for the MMTVneu rat transgene) breeder pairs were obtained from
Jackson Laboratories (Bar Harbor, ME), and controlled breedings
were conducted. Progeny was raised until 4 months of age, at which
time focal mammary tumors began to develop exclusively in females
(100% development by age 6 months). During this time, tumor
development was monitored with weekly palpation and/or caliper
measurements preceding each imaging session and continued for a
number of weeks (enabling a range of tumor sizes for correlative
demonstration of protease activity levels). FVB/NJ mice, the non-
transgenic parental strain (Jackson Laboratories), were screened in
parallel as controls because they typically do not develop spontaneous
tumors in contrast to the spontaneous focal mammary adenocarci-
noma development seen among the MMTVneu females only. The
mouse colony was then divided into two groups so that cathepsins
and MMPs could be assessed in separate animals; this also enabled
accommodation of the spectral properties of the in vivo probes in-
volved. Specifically, this study included 31 MMTVneu transgenic
female mice (21 cathepsins and 10 MMPs) to investigate protease ex-
pression and 3 FVB/NJ as background control animals. The subsets
of experimental animals were dictated by the stochastic nature of the
tumor model as the development of multiple tumors proceeded quite
rapidly after the onset of the primary lesion. Only those animals in
which the primary tumor had not exceeded a critical size were able to
remain for multiple image sessions necessary for longitudinal study.
Furthermore, to provide a sufficient range of tumor specimens per
Figure 1. Multispectral multimodal imaging system schematic.
Configuration allowed for investigations of epi-illumination imag-
ing at two wavelengths (672 and 748 nm).
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size classification used (N ≥ 3; Figure 4), the indicated number of
MMTVneu mice was included.
All animal studies were performed according to protocol approved
by the Institutional Animal Care and Use Committee Review Board
and Massachusetts General Hospital Center for Comparative Medi-
cine. Twenty-four hours before each imaging session, while under iso-
flurane narcosis, mice were shaven and treated with Nair (Church &
Dwight Co., Inc., Princeton,NJ) to remove hair. Also, at this time,mice
received either one of the intravital cysteine protease probes of inter-
est (cathepsin: ProSense 750;MMP:MMPSense 680) as well as a probe
to account for vascularization and biodistribution (AngioSense 680
or 750, respectively; VisEn Medical, Inc., Woburn, MA) by tail vein
injection. Per manufacturer’s recommendations, the in vivo imaging
agents were administered per average 25-g mouse in the following dos-
ages: ProSense 750, 0.08 mg/0.025 kg; MMPsense, 0.09 mg/0.025 kg;
and AngioSense 750/680, 0.05 mg/0.025 kg. Each probe was given in
2-nmol concentrations.
For imaging, animals were anesthetized with ketamine/xylazin and
were positioned in the optical chamber. All animals were softly com-
pressed against a glass window and maintained an approximate thick-
ness of 1.3 cm for ensuring uniform imaging and identical imaging
parameters and placement throughout all measurements. Mice were
then imaged at the onset of lesion development, tumors ranging from
∼1 to 15 mm, with some mice being imaged for several weeks. Once
tumors reached the upper limit of the study (i.e., ∼15 mm) or when
interrogations were completed, animals were euthanized with carbon
dioxide asphyxiation and tumors were harvested and snap frozen for
ex vivo analysis. Smaller tumors were confirmed (i.e., <5 mm) by fol-
lowing their growth over time in longitudinal studies (this growth
followed on a per animal basis every 3-5 days by visual inspection
or fluorescence imaging) and by histology.
Ex Vivo Analysis
Ex vivo analyses were performed to provide correlative biologic
confirmation of the protease activity indicated through noninvasive
in vivo imaging. To do so, various routine ex vivo techniques were
performed to characterize the presence and relative amounts of ca-
thepsins and MMPs required to activate the probes used. The follow-
ing section details the steps required and reasons for each analysis.
Immunohistochemistry. Immunohistochemical analyses were per-
formed to demonstrate immunohistochemical evidence of specific
cathepsin B and MMP-9 expression in extracted tumor regions. Five-
micrometer sections of freshly frozen tumor samples were examined
for expression of cathepsin B (Santa Cruz Biotechnology Inc., Santa
Cruz, CA) or MMP-9 (Abcam, Inc., Cambridge, MA). Biotinylated
secondary antibodies were applied (Vector Laboratories, Burlingame,
CA) as the avidin-biotin peroxidase method (standard Vectastain
ABC Kit; Vector Laboratories) and the AEC Substrate Chromagen
(Dakocytomation, Dako North America, Carpinteria, CA; as per
manufacturer’s recommendations) were used. The red reaction prod-
uct was visualized with 3-amino-9-athyl-carbazol substrate (AEC;
Dakocytomation). Subsequent haemotoxylin counterstaining was per-
formed for all tissues.
Western blots. Given that none of the primary antibodies used in
the immunohistochemical analyses were capable of distinguishing be-
tween latent and active forms of the involved proteases, Western
analysis of the active form of a specific protease was critical in deriv-
ing accurate correlations. As such, densitometric analyses of Western
blots were used to confirm corresponding cathepsin B and MMP-9
protein content of the tumor samples. In short, tumors were excised
(specifically a core and margin sample was taken from each tumor
with a third adjacent sample of mammary adipose collected from
within a 1-cm perimeter of each growth, respectively) and homoge-
nized in lysis buffer. After total protein determination (Pierce BCA
protein assay; Pierce Biotechnology, Rockford, IL), 5 μg of total pro-
tein lysate was subjected to electrophoresis on 12.5% SDS-PAGE fol-
lowed by its transfer to methanol-equilibrated polyvinylidene fluoride
membrane (Bio-Rad Laboratories, Hercules, CA) according to themanu-
facturer’s instructions. Concentrations for blotting anti–cathepsin B,
anti–MMP-9, and HRP-labeled secondary antibody followed manu-
facturer’s recommendations (R&D Systems, Minneapolis MN). The
blots were developed with the enhanced chemiluminescence system
(Amersham Pharmacia Biosciences, Piscataway, NJ). The immunoblot
of GAPDH (R&D Systems) was used as a loading control. Also, ad-
ditional confirmation of heightened enzymatic activity of MMP-9
within tumor samples was provided through densitometric analysis
of its characteristic 97-kDa lysis band apparent after gelatin zymography
(data not shown).
Data Acquisition and Analysis
To tabulate signal strength acquired from epi-illumination imag-
ing, the fluorescent images were exported to ImageJ (National In-
stitutes of Health, Bethesda, MD). The Freehand selections tool in
ImageJ was then used to delineate complete adenocarcinomas by fol-
lowing contours that were of fluorescence strength that was at least
that of the background fluorescence. These contours where referred
to as the ROI (unique shape and number of pixels) for a given tumor.
The ROI was then transposed onto the contralateral mammary fat
pad to obtain a measure of nondiseased tissue fluorescence. Further-
more, these ROIs were used, namely, their size, shape, and location
(determined by x and y coordinates), between the multispectral im-
ages (i.e., images acquired at the two wavelengths of interest) to mini-
mize user bias and variances between the same animal. Once the
contour areas had been determined, mean signals were obtained from
the ROIs using the Measure feature found under the Analyze drop-
down menu.
A similar protocol was used to obtain quantitative information
from the Western blots. Specifically, densitometry was performed
on the radiographs generated from each of three separate Western
analyses (i.e., core, margin, and adjacent tissues) for each tumor
using ImageJ software. In particular, the active protease bands on
the Western blots for each individual tissue sample were delineated,
and mean values were tabulated and added to produce a singular
value for active protease. To generate a measure of the total protease
expression ex vivo at the protein level, the mean signal values from
the core, margin, and adjacent tissue Western blots were then com-
bined for each tumor. The rationale for collecting tissue specimens in
this manner stems from the reports of macrophages, stromal fibro-
blasts adjacent to the tumor, as well as carcinoma cells themselves
expressing varying degrees of cathepsin B in a variety of solid tumors
[18], including breast cancer [19]. Similar data on spatially varying
MMP-9 expression have been collected regarding tumoral and stromal
cells. In fact, elevation of stromal MMP-9 levels has been associated
with more aggressive poorly differentiated lesions [20–22] relative to
that of survival advantage inferred with greater MMP-9 expression
within the carcinoma cells themselves.
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Data are presented as mean ± SD. Statistical analysis of in vivo
tumor fluorescence was conducted using a 2-tailed, unpaired Stu-
dent’s t-test (where N = 21, 10, and 31 for ProSense, MMPsense,
and AngioSense, respectively), or a single-factor analysis of variance
(ANOVA; where N ≥ 3 for each subset). In both cases, a P value of
≤.05 was considered to be statistically significant.
Results
In Vivo Epi-illumination Imaging
Inspection of raw images acquired by near-infrared fluorescence
reflectance imaging (NFRI) revealed that cancerous regions were
clearly visible based solely on signal intensities for each probe. Col-
lectively, findings from 31 mice (21 ProSense and 10 MMPSense)
are shown in Figure 2. As observed, tumor fluorescence is 2.2, 2.0,
and 1.9 times higher than background fluorescence measured in con-
tralateral mammary fat pad tissue for ProSense, MMPSense, and
AngioSense, respectively. Further analysis confirms that tumor signals
are statistically higher (unpaired Student’s t-test) than nondiseased
mammary fat pad tissue as evident by P values <.05. Specifically,
P values >.01 for ProSense, MMPSense, and AngioSense.
Despite fluorescence signals being elevated in cancerous regions,
fluorescence intensities corresponding to protease activities did not
deviate considerably between tumor sizes/progressions. This is visu-
ally evident in the example provided in Figure 3 and is further sub-
stantiated for all cases in Figure 4. In particular, Figure 3 displays
dual-wavelength in vivo epi-illumination images acquired from two
different mice, both mice being 5 months old, that have developed
mammary tumors of varying sizes and developmental stages. The
top panel presents an interrogation of cathepsin protease activity in
a mouse with two tumors (L: 13 × 13 mm and M: 8 × 8 mm),
and the bottom panel presents an interrogation of MMP protease
activity in a mouse with three tumors (M: 9 × 6 and 10 × 8 mm
and S: 3 × 3 mm). White light images are provided to identify the
tumor category and location; where S, M, and L stand for small, me-
dium, and large tumors (Figure 3A). Shown in Figure 3B are the
fluorescent signals obtained from the AngioSense marker, which re-
late to vascularization and the biodistribution of the protease probes.
Here, it is observed that AngioSense does accumulate in the can-
cerous region and that fluorescence intensities do vary considerably
between tumors. However, consulting Figure 3C , we see that al-
though fluorescence from protease probes is higher in diseased tissue
compared with healthy tissue (outlying mammary fat pad), tumor
size/development is undetectable by monitoring cysteine protease
Figure 2. In vivo NFRI signals obtained from tumor and nondiseased
contralateral mammary fat pad (CMFP) tissue for each probe of inter-
est. All signal values obtained from adenocarcinomas are statistically
higher than background; however, ProSense expression is detected
at a much higher extent compared withMMPSense. AngioSense is a
nonspecific probe used in this study to account for probe delivery.
Figure 3. In vivo dual-wavelength epi-illumination images of cysteine protease expression in transgenic mammary tumor-forming mice.
(A) White light image identifies tumor location and category: S indicates small, M, medium, L, large tumors. (B) AngioSense channel
shows an accumulation of probe in tumor and represents vascularization and biodistribution of activatable probe. (C) Protease channel
(either ProSense or MMPSense) shows accumulation of probe in tumor, but tumor size is not ascertainable by expression levels. (D)
Superposition of protease signal divided by AngioSense signal with white light image shows how dual-wavelength/normalization ap-
proach can improve the observation accuracy.
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expressions only. Particularly, mean fluorescence values obtained from
delineating the entire lesion produces values independent of malig-
nancy growth. These results are most evident in the ProSense epi-
illumination image (Figure 3C , top panel ), where protease expression
level alone functions as a poor correlate of lesion size. Nevertheless, as
observed in Figure 3D, when cysteine protease expressions are cor-
rected for by an internal control that accounts for probe delivery, ma-
lignancies are discernible by size and developmental stage. In fact, by
normalizing protease expressions to their equivalent biodistribution,
signal values become two to three times higher between each tumor
category (i.e., small, medium, and large).
Figure 4 confirms the findings presented in Figure 3 for the entire
data set used to compare in vivo measurements with the ex vivo tests
preformed herein. Specifically, Figure 4 shows results from 12 mice
(14 tumors) from the cathepsin protease data set (Figure 4, A and B)
and 6 mice (13 tumors) from the MMP protease data set (Figure 4,
C and D). As observed, raw ProSense and MMPSense expression
obtained from cancerous regions remains fairly constant for tumors
of various sizes, which is not due to the lack of available protease
probe as confirmed by the AngioSense signal (Figure 3, A and C ,
respectively). In fact, by grouping growths into categorical areas
(N ≥ 3 for each category) and performing a single-factor ANOVA,
we find that overall fluorescent protease expression does not statis-
tically increase for larger tumors (∼1 cm or more in length and width)
beyond the levels seen for medium- (5-10 mm in length and width)
or smaller- (5 mm or less in length and width) diameter tumors
for both protease activatable probes (P values of .210 and .126 for
ProSense and MMPSense, respectively). Note that tumor size was
calculated as a two-dimensional measure using caliper measurements
of a long and a short axis. The areas calculated were consistent with the
area seen on the white light images at all cases where the tumor was
clearly visible.
Nevertheless, given that expression levels remain nearly constant
among lesions, the data indicate considerable capacity for successful
identification of tumors as small as 2 mm in diameter by investigat-
ing molecular signatures. However, taking a similar approach but in-
stead dividing the fluorescent signals of either ProSense or MMPSense
to their corresponding biodistribution signals (i.e., AngioSense), we
see that a possible correction is available to monitor protease expres-
sion as a function of tumor size (Figure 4, B and D, respectively).
Furthermore, as confirmed by P values < .01 (single-factor ANOVA),
this method provides a way to monitor disease progression (i.e.,
Figure 4. In vivo protease signals from tumors of various sizes either plotted with or normalized to corresponding vascular signals. Raw
mean ProSense (A) and MMPSense (C) along with AngioSense signals for each tumor. As seen, protease expressions remain rather
constant and are statistically independent of tumor size, which is not caused by a lack of available protease probe at the cancerous
region as evident by AngioSense signals. Mean ProSense (B) and MMPSense (D) expressions normalized to respective biodistribution
signals (AngioSense) for tumors of different categorical areas. This internal control provides a statistically relevant way to observe dis-
ease progression.
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increasing protease expression over time) in vivo from both ProSense
and MMPSense signals.
Ex Vivo Correlative Studies
Immunohistochemistry showed clear up-regulation of cathepsin-B
as well as MMP-9 from harvested tumors, which represent key
enzymes for probe activation of ProSense and MMPSense, respec-
tively. As such, signals acquired at tumor sites are undoubtedly from
probe activation and, moreover, from proteases known to be over-
expressed in aggressive tumors. Correlative ex vivo histology confirmed
the initial imaging findings in that exposure times are considerably less
for investigations with ProSense over MMPSense, suggesting that
higher accumulation and expression of the ProSense marker was
occurring. Furthermore, as seen in Figure 5, correlative ex vivo his-
tology shows a strikingly improved correlation with in vivo measure-
ments when protease signals are corrected for probe delivery. More
specifically, Figure 5 represents how raw ProSense (Figure 5A) and
MMPSense (Figure 5C ) in vivo signals show no correlation with the
true protein levels, but when ProSense (Figure 5B) and MMPSense
(Figure 5D) signals are corrected by their biodistribution (i.e., divi-
sion with the AngioSense signals), the in vivo signals correlate to the
underlying physiology and true protein levels contained in the tu-
mors, as seen by the improved values for the coefficient of determi-
nation (R2).
Discussion
An increasing number of optical imaging studies have shown the
ability to visualize cellular and subcellular processes in intact tissues
[1–10,23–27] after the development of several technologies to fluores-
cently tag tissue, disease, and therapeutic efficacy biomarkers in vivo
[8,9,28–35]. Although the feasibility and value of fluorescence imag-
ing have been amply demonstrated, it has become crucial to develop
strategies that accurately report on the underlying cellular and sub-
cellular activities. To improve quantification, approaches that ac-
count for the effects of the tissue optical heterogeneity and the
fluorescence activity depth on signal intensity have been considered
[36]. Such methods typically focus on the use of physical models of
photon propagation in tissue to analytically correct for propagation
effects. In this study, we addressed a remaining important aspect of
imaging accuracy, that is, the separation of probe uptake and target
presence, with the ultimate goal of accurately quantifying the actual
target presence. The underlying limitation considered is that the light
Figure 5. In vivo fluorescence signals plotted against ex vivo signals obtained by Western blot analyses. Mean ProSense (A) and
MMPSense (C) signals plotted against corresponding total protein level expressions. Mean ProSense (B) and MMPSense (D) normalized
to drug delivery (i.e., divided by AngioSense) plotted against corresponding total protein level expressions. Normalizing in vivo protease
signals with biodistribution signals allows for an internal correction that also provides an improved correlation to the underlying physiology.
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strength recorded in vivo using a fluorescent probe with specificity to
a certain target depends on the amount of the target present and the
efficiency of the probe uptake. The most obvious shortcoming is that
the absence of fluorescence signal, for example, can be any combina-
tion of lack of target or lack of delivery/uptake at the time point of
observation making the interpretation of the corresponding single-
wavelength measurement highly unreliable.
For this reason, we used a dual-probe/dual-wavelength approach
to establish an internal control, that is, a background measurement
from the same animal where the target measurement was acquired
from. This has been showcased herein by using a common protease
activatable probe (in one spectral channel) for visualizing a tumor
biomarker, together with a probe of similar biodistribution (in a sep-
arate spectral channel) which corresponded to probe delivery. In this
approach, an identical molecule to the activatable probe (but with-
out the activation mechanism) was used to reveal background and
tumor uptake. However, more generally, this technique can also be
used with targeted probes (such as antibody-, antibody fragment–, or
peptide-based probes) where the targeting capacity (affinity) mecha-
nism of the control probe is scrambled to prevent binding.
We further selected a model of spontaneous breast cancer, which
more closely resembles human tumor development compared with
mouse models inoculated with cancer cells. In vivo measurements
demonstrated a variation in probe uptake by different tumors and
tumor sizes. Compared with single-wavelength (uncorrected) mea-
surements, dual-wavelength protease measurements corrected for
probe uptake exhibited significantly better correlation with the pro-
tease content, as recorded by densitometry analysis performed on
standardized Western blots. Regarding malignancy detection, we
found that tumors as small as 2 to 3 mm in diameter demonstrated
a 2:1 contrast over background and that protease expression did not
statistically increase for larger tumors (∼1 cm or more in length and
width) beyond the levels measured from smaller lesions (5 mm or
less). These data may also prove relevant for primary tumor detection
or as a biomarker in monitoring therapeutic response, for instance, to
inhibitor compounds being introduced to clinical trials.
In summary, the data in this article were reported using epifluo-
rescence imaging, which is limited to surface weighting observations,
that is, 2- to 3-mm sampling depth. An additional advantage of the
dual-wavelength method in epi-illumination measurements is that
changes in signal strength due to depth or optical heterogeneity (darker
lesions vs lighter lesions) do not significantly affect the corrected mea-
surement. However, this correction technique applies so long as the
two emission bands are spectrally close to each other and lie in the
near infrared—where relatively small attenuation variations are pres-
ent as a function of wavelength. Regardless, the use of tomographic
methods with the dual-wavelength approach could further improve
quantification and offer a three-dimensional picture of fluorochrome
biodistribution. As such, the use of dual-wavelength imaging for es-
tablishing internal controls can 1) offer a more accurate strategy in
cases where probe uptake may exhibit variations, 2) offer more accu-
rate biologic observations in vivo, and 3) be extended to multiple
wavelengths which, typically in pairs, could offer improved observa-
tion accuracies of more than one target.
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